Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254826 · ClinicalTrials.gov registry record · Phase 1
Yellow Fever Virus Vaccine and Immune Globulin Study
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00254826 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 80 participants.
The verdict
NCT00254826, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether immune globulin can limit the amount of yellow fever vaccine virus present in the blood after vaccination without compromising the immunity associated with the yellow fever vaccine. The study will enroll 80 participants in two groups of 40 each. The first group will receive the yellow fever vaccine with salt-water placebo. The second group will receive yellow fever vaccine with immune globulin. The amount of vaccine virus and immune response in both groups will be compared. Yellow fever vaccine has been used to protect humans against Yellow Fever Vaccine disease since the 1930s.
Interventions
- BIOLOGICAL YF-VAX® plus saline
- BIOLOGICAL 17D YF Vaccine plus Ig,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254826
The ClinicalTrials.gov registry entry for NCT00254826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which YF-VAX® plus saline is the first listed.
NCT00254826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254826 about?
NCT00254826 is a clinical study titled "Yellow Fever Virus Vaccine and Immune Globulin Study". The purpose of this study is to determine whether immune globulin can limit the amount of yellow fever vaccine virus present in the blood after vaccination without compromising the immunity associated with the yellow fever vaccine. The study will enroll 80 participants in two groups of 40 each. The ...
What is the current status of trial NCT00254826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2006-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00254826?
The interventions under investigation include: YF-VAX® plus saline (BIOLOGICAL), 17D YF Vaccine plus Ig, (BIOLOGICAL).
Who is sponsoring clinical trial NCT00254826?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.